- Home
- BRIA vs RVPH Comparison
BRIA vs RVPH Comparison
Compare BRIA & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRIA
- RVPH
- Stock Information
- Founded
- BRIA 2011
- RVPH 2006
- Country
- BRIA Singapore
- RVPH United States
- Employees
- BRIA N/A
- RVPH N/A
- Industry
- BRIA
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- BRIA
- RVPH Health Care
- Exchange
- BRIA NYSE
- RVPH Nasdaq
- Market Cap
- BRIA 76.2M
- RVPH 88.0M
- IPO Year
- BRIA 2024
- RVPH N/A
- Fundamental
- Price
- BRIA $3.02
- RVPH $1.57
- Analyst Decision
- BRIA
- RVPH Strong Buy
- Analyst Count
- BRIA 0
- RVPH 5
- Target Price
- BRIA N/A
- RVPH $11.40
- AVG Volume (30 Days)
- BRIA 15.2K
- RVPH 1.4M
- Earning Date
- BRIA 03-04-2025
- RVPH 04-14-2025
- Dividend Yield
- BRIA N/A
- RVPH N/A
- EPS Growth
- BRIA N/A
- RVPH N/A
- EPS
- BRIA 92.24
- RVPH N/A
- Revenue
- BRIA $55,755,669.00
- RVPH N/A
- Revenue This Year
- BRIA N/A
- RVPH N/A
- Revenue Next Year
- BRIA N/A
- RVPH N/A
- P/E Ratio
- BRIA $0.03
- RVPH N/A
- Revenue Growth
- BRIA 8.03
- RVPH N/A
- 52 Week Low
- BRIA $2.90
- RVPH $0.60
- 52 Week High
- BRIA $4.38
- RVPH $4.45
- Technical
- Relative Strength Index (RSI)
- BRIA N/A
- RVPH 35.98
- Support Level
- BRIA N/A
- RVPH $1.66
- Resistance Level
- BRIA N/A
- RVPH $1.88
- Average True Range (ATR)
- BRIA 0.00
- RVPH 0.16
- MACD
- BRIA 0.00
- RVPH -0.05
- Stochastic Oscillator
- BRIA 0.00
- RVPH 7.20
About BRIA BRILLIA INC
BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.